MENU
+Compare
RGNX
Stock ticker: NASDAQ
AS OF
Dec 26, 04:59 PM (EDT)
Price
$7.89
Change
+$0.49 (+6.62%)
Capitalization
366.63M

RGNX REGENXBIO Forecast, Technical & Fundamental Analysis

a developer of gene therapy treatments

Industry Biotechnology
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for RGNX with price predictions
Dec 24, 2024

RGNX's RSI Oscillator climbs out of oversold territory

The RSI Oscillator for RGNX moved out of oversold territory on December 20, 2024. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In of the 34 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where RGNX advanced for three days, in of 283 cases, the price rose further within the following month. The odds of a continued upward trend are .

RGNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 11, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on RGNX as a result. In of 106 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for RGNX turned negative on December 12, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .

RGNX moved below its 50-day moving average on December 10, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for RGNX crossed bearishly below the 50-day moving average on November 22, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGNX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for RGNX entered a downward trend on December 24, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.216) is normal, around the industry mean (18.292). P/E Ratio (0.000) is within average values for comparable stocks, (87.498). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.756). RGNX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (4.193) is also within normal values, averaging (260.038).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. RGNX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
RGNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

RGNX is expected to report earnings to fall 3.42% to -112 cents per share on March 04

REGENXBIO RGNX Stock Earnings Reports
Q4'24
Est.
$-1.13
Q3'24
Missed
by $0.05
Q2'24
Beat
by $0.24
Q1'24
Missed
by $0.12
Q4'23
Missed
by $0.16
The last earnings report on November 06 showed earnings per share of -116 cents, missing the estimate of -112 cents. With 558.88K shares outstanding, the current market capitalization sits at 366.63M.
A.I. Advisor
published General Information

General Information

a developer of gene therapy treatments

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
9804 Medical Center Drive
Phone
+1 240 552-8181
Employees
344
Web
https://www.regenxbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
TILWX29.740.36
+1.23%
Nuveen Large Cap Growth W
SPGIX42.050.44
+1.06%
SEI Large Cap Growth I (SIMT)
EGOCX17.280.17
+0.99%
Allspring Large Cap Core C
MRVYX12.020.02
+0.17%
Mirova International Sustainable Eq Y
GCIFX13.890.01
+0.07%
Green Century MSCI Intl Indx Instl

RGNX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with BEAM. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
+0.27%
BEAM - RGNX
49%
Loosely correlated
+0.38%
DNLI - RGNX
49%
Loosely correlated
+0.67%
AXON - RGNX
48%
Loosely correlated
+1.14%
CRSP - RGNX
46%
Loosely correlated
+1.14%
RCKT - RGNX
43%
Loosely correlated
+2.19%
More